Key Takeaways
- IBI Ag has finalized its proof of concept (POC) for the industry’s first AI platform capable of designing novel bioinsecticide proteins from scratch (de novo).
- The new proteins were successfully validated in insect bioassays, effectively targeting key agricultural pests while protecting beneficial species.
- This computational approach utilizes proprietary biological data and IP to create proteins with enhanced stability, longer shelf life, and lower production costs.
- The breakthrough enables the company to target agricultural challenges previously unreachable with naturally occurring proteins.
- IBI Ag plans to transition to greenhouse and field trials in upcoming growing seasons to accelerate its commercial development pipeline.
IBI Ag Reaches A Milestone
IBI Ag Ltd., a developer of sustainable agricultural biotechnology, has reached a critical milestone with the successful proof of concept of its artificial intelligence platform. This system is designed for the de novo creation of bioinsecticide proteins—molecules engineered from the ground up rather than modified from nature.
By utilizing AI to simulate protein-pest interactions, IBI Ag can computationally design solutions that are highly selective. This precision ensures that while target pests are effectively managed, beneficial insects and the surrounding ecosystem remain unharmed, addressing a primary limitation of traditional chemical pesticides.
Commercial and Environmental Advantages
The transition to a digital design platform allows IBI Ag to bypass many of the traditional bottlenecks in bioinsecticide development. The computational nature of the platform significantly reduces the time required to discover viable candidates, offering a faster and more cost-effective path to market.
Beyond speed, the de novo proteins are designed with commercial viability in mind. The platform optimizes for industrial resilience, including improved stability and a longer shelf life, which are common hurdles for biological products. These advancements are expected to lower production costs and improve the reliability of the products for end-users in the agricultural sector.
Leadership on IBI Ag Technology and Industry Impact
The completion of this POC marks the first time such a platform has been applied specifically to the bioinsecticide market. Management believes this data-driven methodology will be a defining factor in the future of sustainable farming.
“Completing this proof of concept is a major milestone for IBI Ag,” said Arnon Heyman, CEO of IBI Ag. “To the best of our knowledge, this is the first ever de novo protein design platform for bioinsecticides. It is designed to leverage the company's proprietary IP for targets in insect control. This allows us to discover and validate new proteins based on vast amounts of data which we believe is a game-changer in the industry.”
Next Steps: Moving IBI Ag Solutions to the Field
Following the successful validation in insect bioassays, IBI Ag is preparing to expand its research into more complex environments. The company has announced plans for a series of greenhouse and field trials scheduled for the upcoming growing seasons.
“This advancement not only demonstrates our commitment to sustainability but also supports farmers in achieving higher yields without compromising the health of ecosystems,” Heyman added. Through these next phases of testing, IBI Ag aims to solidify partnerships with global agricultural stakeholders to bring these AI-designed biological solutions to the commercial market.
